A wearable robot weighing just under one kilogram improves knee function in children living with spinal muscular atrophy (SMA ...

Atossa Therapeutics, Inc. (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced ...

CureDuchenne, a global leader in funding and advancing research for Duchenne muscular dystrophy, today announced a second investment into Tevard Biosciences to support the advancement of the company's ...

Strong Buy on WVE-N531 and WVE-006 catalysts, Phase data, and cash runway into 2028. Click for this WVE stock update.

EMA primary endpoint qualification of Stride Velocity 95th centile for Duchenne muscular dystrophy: Vernon, France Wednesday, August 9, 2023, 15:00 Hrs [IST] Sysnav Healthcare ann ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...

Columnist Shalom Lim is grateful for the opportunity to use his lived experience to do good work on behalf of people with DMD ...

Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function ...

A working group on the treatment of Duchenne muscular dystrophy patients will be created within the Georgian Patriarchate, ...